Belgian immunology developer Agomab Therapeutics and ocular drug delivery company SpyGlass Pharma priced listings on Nasdaq, collectively raising about $350 million. Agomab secured roughly $200 million via American depositary shares while SpyGlass raised about $150 million, expanding investor access to niche immunology and ophthalmology programs. The deals follow a busy week of biotech listings and signal renewed appetite for capital in later-stage and specialized drug developers. Market participants will watch early trading and how proceeds are allocated to clinical milestones and commercialization plans.